Table 1 Demographics, breast cancer, tamoxifen use and co-medications use characteristics in the overall population in the study
From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
Characteristics (N= 245) | N/mean | Percent/SD |
|---|---|---|
Mean age (years) a | 47.46 | ± 9.7 |
Self-report ethnicity | Â | Â |
   Caucasian | 166 | 67.76 |
   Asian/East Asian | 56 | 22.86 |
   African American/Black | 2 | 0.82 |
   Latina/Hispanic | 14 | 5.71 |
   Pacific Islander | 1 | 0.41 |
   Other/mixed | 3 | 1.22 |
   Declined/refused/do not know | 3 | 1.22 |
Number married (yes) | 176 | 72 |
Number full-time working | 98 | 40 |
Education levels | Â | Â |
   High school graduated or less | 6 | 2.45 |
   Some college | 36 | 14.69 |
   College graduated | 90 | 36.73 |
   Completed post-graduate degree | 105 | 42.86 |
   Declined/refused | 8 | 3.27 |
Socio-economic status | Â | Â |
   Income < $50, 000 | 29 | 11.84 |
   Income ≥$50, 000 to < $100, 000 | 56 | 22.86 |
   Income ≥$100, 000 | 108 | 44.07 |
   Declined/refused | 52 | 21.23 |
Reported other health problems | 91 | 38 |
Breast cancer characteristics | Â | Â |
   Breast cancer (yes) | 237 | 97 |
   Had invasive breast cancer | 165 | 70 |
   Surgery (yes) | 231 | 98 |
   Had lumpectomy | 119 | 52 |
Menopausal status at diagnosis | Â | Â |
   Pre-menopausal | 184 | 78 |
   Post-menopausal | 51 | 22 |
Mean age at menopause (years) a | 45.61 | ± 6.79 |
Had natural menopause | 35 | 22.73 |
Menopause due to chemotherapy treatment | 74 | 48.05 |
Previous used of hormone therapy | 37 | 15 |
Tamoxifen use | Â | Â |
   Ever prescribed | 191 | 78 |
   Ever taken | 171 | 70 |
   Currently taking | 166 | 68 |
Common side effects attributed to tamoxifen | Â | Â |
   Hot flashes | 154 | 63 |
   Sleep problems | 113 | 46 |
   Vaginal dryness | 90 | 37 |
Co-medications/ CYP2D6 inhibitors | Â | Â |
   Strong inhibitors |  |  |
Paroxetine | 1 | 0.41 |
Bupropion | 8 | 3.26 |
   Moderate inhibitors |  |  |
Sertraline | 8 | 3.26 |
Duloxetine | 3 | 1.22 |
   All other inhibitors |  |  |
Amitriptyline | 2 | 0.82 |
Amlodipine | 2 | 0.82 |
Celecoxib | 2 | 0.82 |
Ceterizine | 2 | 0.82 |
Citalopram | 6 | 2.45 |
Diphenhydramine | 3 | 1.22 |
Escitalopram | 6 | 2.45 |
Imipramine | 1 | 0.41 |
Loratadine | 3 | 1.22 |
Nortriptyline | 1 | 0.41 |
Ranitidine | 1 | 0.41 |
   Other co-medications |  |  |
Gabapentin | 10 | 4.00 |
Trazodone | 2 | 0.82 |
Venlafaxine | 15 | 6.12 |
Referral method | Â | Â |
   Physician/nurse referral | 196 | 80 |
   Self-referred or breast cancer support group referral | 11 | 4 |
   Study contact letter | 38 | 16 |
Previous knowledge of CYP2D6 testing (yes) | 122 | 50 |
Source of CYP2D6 testing knowledge | Â | Â |
   Physician or nurse | 46 | 38 |
   Newspaper | 5 | 4 |
   Television | 1 | 1 |
   Internet | 17 | 14 |
   Medical literature | 24 | 20 |
   Other | 27 | 22 |
   Unknown/missed | 2 | 1 |